HOME >> MEDICINE >> NEWS
Cell Pathways' Aptosyn™ (exisulind) shows continuing long-term prevention of colon polyps in FAP patients

Results of Phase III Trial and Extension Study Data Presented by Cleveland Clinic Investigator at American Gastroenterological Association Meeting

Clinical results from familial adenomatous polyposis (FAP) patients treated with Aptosyn™(exisulind) for up to 18 months were presented today at the annual meeting of the American Gastroenterological Association (AGA) by Carol Burke, M.D. of the Cleveland Clinic Foundation. Results of a one year double-blinded, placebo-controlled Phase III trial and its six month open-label extension, sponsored by Cell Pathways, Inc. (Nasdaq: CLPA), demonstrate that Aptosyn™ induces a clinically significant reduction in the formation of precancerous colon polyps in patients with FAP after as little as six months of therapy. Moreover, patients who have continued on Aptosyn™ for more than one year continue to show further improvement over time.

In a separate release the company announced the presentation of preclinical research being presented at AGA showing that colonic tumor cells marked by hereditary defects different from the APC gene mutation that characterizes FAP also undergo apoptosis, or programmed cell death, when treated with Aptosyn. The company also reported laboratory findings that the cyclic GMP phosphodiesterase targeted by Aptosyn™ and other selective apoptotic antineoplastic drugs (SAANDs) is over-expressed in colonic neoplasias relative to normal colonic mucosal tissue. This observation may explain in part the selectivity of SAANDs for precancerous and cancerous cells and not for normal tissue.

Results of Phase III Trial and Extension Study

"Based on the clinical responses that we have observed to date, use of exisulind for the chemoprevention of colonic adenomas has the potential to significantly alter the management of patients with FAP," commented Dr. Burke, a principal investigator for the Phase III study and for the previous Phase II trial of Aptosyn&
'"/>

Contact: Joan Kureczka, J. Kureczka Assoc.
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
22-May-2000


Page: 1 2

Related medicine news :

1. Study shows promise in identifying kidney failure
2. Study shows patch therapy may be as effective as oral medications
3. Study shows soy is well accepted in school lunches
4. Chronic pain treatments more effective when taken together, new study shows
5. UW study shows blacks and Latinos are more satisfied with physicians of the same race
6. Vaccine against childhood pneumonia shows promise
7. UW research shows risk factors for relapse among health care professionals who abuse drugs
8. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
9. New technique shows promise for improved straightening of crooked nose
10. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
11. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... August 15, 2019 , ... Jon O'Brien, president of Catholics ... clinics to provide written assurance that they will comply with the Trump Administration’s ... Gag Rule, the new policy restricts providers and clinics that receive federal Title ...
(Date:8/14/2019)... ... August 14, 2019 , ... ScribeAmerica, the nation’s most ... a place on the Inc. magazine 500/5000 list today for the ninth consecutive ... of ScribeAmerica’s recognition as one of the fastest growing companies in America. ...
(Date:8/14/2019)... ... , ... In a recent Trivedi Effect workshop, Master Dahryn Trivedi spoke about ... “Doubt can obliterate your old beliefs,” said Master Dahryn. “Doubt helps you look at ... understanding and your awareness. Trust that the Divine has put you here for a ...
(Date:8/12/2019)... ... 2019 , ... Eco Pump Services is an experienced, licensed, and ... over 25 years, Eco Pump Services has served customers with excellence and exceptional customer ... Eco Pump’s steady five-star ratings and excellent customer reactions throughout numerous online review sources ...
(Date:8/12/2019)... ... 2019 , ... Injured veterans from across the U.S. will ... annual Lockton Warfighter Sports Charity Challenge being held on September 9 at Trump ... event again this year will be fifty wounded warfighters and Craig Stadler, 1982 ...
Breaking Medicine News(10 mins):
(Date:8/17/2019)... ... August 17, 2019 , ... Inc. Magazine Unveils Its Annual ... No. 2502 on the 2019 Inc. 5000 with Three-Year Revenue Growth of 157% ... recruitment firm is No. 2502 on its annual Inc. 5000 list, the most ...
(Date:8/16/2019)... ... August 16, 2019 , ... SignatureCare Emergency Center has ... Houston, TX including Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day ... Heights, is aimed at helping Houston families get their children caught up on ...
(Date:8/16/2019)... NEW YORK (PRWEB) , ... August 16, 2019 ... ... first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting ... that there are around 150 million people worldwide that are affected by treatment-resistant ...
Breaking Medicine Technology:
Cached News: